Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13155039 | 0.95 | MEN1 (0.50) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL31465204 | 0.93 | MEN1 (0.49) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL21680263 | 0.85 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2POLBMAPTKDM4E | |
| SCHEMBL17886653 | 0.82 | USP2 (0.44) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL2673712 | 0.82 | ADORA1 (0.46) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL2330634 | 0.82 | MEN1 (0.63) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL26970143 | 0.81 | MEN1 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL2397782 | 0.81 | ADORA1 (0.46) | KMT2ASMN1; SMN2HPGDADORA1GRM5 | |
| SCHEMBL16554034 | 0.81 | KMT2A (0.58) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4408862 | 0.80 | ALDH1A1 (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088093-B | Acyl sulfonamide nav1.7 inhibitors | 百时美施贵宝公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2022087216-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3357925-B1 | SALT TYPE AND CRYSTAL TYPE OF 4H-PYRAZOLO [1, 5-ALPHA]BENZIMIDAZOLE COMPOUND AND PREPARATION METHOD AND INTERMEDIATE THEREOF | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3357925-B1 | SALT TYPE AND CRYSTAL TYPE OF 4H-PYRAZOLO [1, 5-ALPHA]BENZIMIDAZOLE COMPOUND AND PREPARATION METHOD AND INTERMEDIATE THEREOF | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3532462-B1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3532462-B1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10941150-B2 | Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2021-03-09 | — | — | US | disclosed |
| US-10941150-B2 | Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2021-03-09 | — | — | US | disclosed |
| CN-108137598-B | Salt form and crystal form of 4H-pyrazolo [1, 5-alpha ] benzimidazole compound, and preparation method and intermediate thereof | 湖北生物医药产业技术研究院有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| WO-2007047496-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1761491-A1 | NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| US-20060183904-A1 | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-08-17 | — | — | US | disclosed |
| US-20060128752-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| EP-1613601-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co. Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2006001752-A1 | NOVEL PIPERIDINE/8-AZABICYCLO [3.2.1] OCTAN DERIVATIVES AS MODUILATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | WO | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004089307-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO. INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941150-B2 | Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | BRI3BP, REN, SCN4A | MEN1 1401/4885KMT2A 860/4885ALDH1A1 711/4885 |
| US-20060183904-A1 | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | MEN1 1517/4885KMT2A 1132/4885ALDH1A1 1882/4885 |
| US-20060128752-A1 | Chemical compounds | HTR7, NPSR1, TACR2 | MEN1 1789/4885KMT2A 3763/4885ALDH1A1 4078/4885 |
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | SCN7A, SCN1A, SCN8A | MEN1 3321/4885KMT2A 1848/4885ALDH1A1 1169/4885 |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | MEN1 4561/4885KMT2A 4565/4885ALDH1A1 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.